IFU
NBIX icon

iSAM Funds (UK)’s Neurocrine Biosciences NBIX Stock Holding History

iSAM Funds (UK)’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,632
Closed -$931K – 573
2025
Q3 		$931K Buy
6,632
+3,373
+103% +$457K 0.19% 163
2025
Q2 		$410K Buy
+3,259
New +$374K 0.09% 305
2024
Q3 		– Sell
-1,701
Closed -$234K – 368
2024
Q2 		$234K Buy
+1,701
New +$233K 0.18% 195
2023
Q3 		– Sell
-4,745
Closed -$447K – 303
2023
Q2 		$447K Buy
+4,745
New +$464K 0.4% 106

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

iSAM Funds (UK)'s NBIX Position: Q4 2025 in Review

iSAM Funds (UK) sold out of Neurocrine Biosciences (NBIX) in Q4 2025, closing a stake of 6,632 shares — an estimated $931K sold.

iSAM Funds (UK) first reported a position in NBIX in Q2 2023 and held it in 4 quarters. The position peaked at $931K in Q3 2025. 732 funds tracked by Wall St. Rank hold NBIX as of Q4 2025.

  • iSAM Funds (UK) reported no remaining Neurocrine Biosciences position as of Q4 2025 after selling out during the quarter.
  • iSAM Funds (UK) sold 6,632 Neurocrine Biosciences shares in Q4 2025, an estimated $931K.
  • iSAM Funds (UK) first reported a position in Neurocrine Biosciences in Q2 2023 and held it in 4 quarters.
  • iSAM Funds (UK)'s Neurocrine Biosciences position peaked at $931K in Q3 2025.
  • 732 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2025.

Based on iSAM Funds (UK)'s 13F filing for Q4 2025, filed 17 Feb 2026.